Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Galena Biopharma downgraded to Hold at Maxim Group (1.28)Maxim Group downgrades GALE to Hold from Buy. Upon the announcement of Galena's CEO Dr. Mark Schwartz's departure Tuesday evening, the Board of Directors (BOD) announced that it will engage an independent advisory firm to evaluate the company and determine the best strategic path forward; including sale of the company, a merger or reverse merger, or remain a stand-alone entity. Galena reported $24.5M in cash at the of 3Q16. Given the uncertainty around the path forward, firm believes it is prudent to downgrade. Operating expenses for 2017 have been reduced as the P3 trial of GALE-401 will not initiate (for now) and the investigator-sponsored studies of NeuVax have only minor costs associated with them. <strong>From a clinical perspective, they believe that NeuVax and GALE-401 have potential in breast cancer and essential thrombocythemia (ET), respectively. However, from a corporate perspective, the uncertainty about the company's future and no visibility on timing around resolution of these issues lends credence to firm's downgrade.</strong></td> </tr></table>"